Tianjin Pharmaceutical announced that Jinyao Heping, a holding subsidiary of the company, participated in the 12th batch of centralized procurement of national drugs. The compound potassium hydrogen phosphate injections are to be selected. The proposed selection price is 0.89 yuan/branch. The procurement period starts from the date of implementation of the selection results to December 31, 2029. The product's sales revenue for 2025 was 11.4871 million yuan, accounting for 0.40% of the company's 2025 revenue; sales revenue for the first quarter of 2026 was 915,700 yuan, accounting for 0.15% of the company's revenue for the first quarter of 2026.

Tianjin Pharmaceutical announced that Jinyao Heping, a holding subsidiary of the company, participated in the 12th batch of centralized procurement of national drugs. The compound potassium hydrogen phosphate injections are to be selected. The proposed selection price is 0.89 yuan/branch. The procurement period starts from the date of implementation of the selection results to December 31, 2029. The product's sales revenue for 2025 was 11.4871 million yuan, accounting for 0.40% of the company's 2025 revenue; sales revenue for the first quarter of 2026 was 915,700 yuan, accounting for 0.15% of the company's revenue for the first quarter of 2026.